Payment overview · 2025
General Payments
$200.77
11 reported records · 8 companies
Healthcare provider profile · identity verified
Jessica Carpenter, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MOUNT VERNON, KY · NPI 1225640022
Verified facts
What the public records show
CMS Open Payments records show Jessica Carpenter, APRN received $200.77 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.16 | 29.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.77 | 17.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.05 | 13.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.52 | 9.7% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $16.22 | 8.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.43 | 7.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.89 | 7.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.73 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $200.77 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $58.16 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.77 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 198 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 193 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 186 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 53 |
| Omeprazole | Omeprazole | 143 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 45 |
| Furosemide | Furosemide | 124 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 41 |
| Montelukast Sodium | Montelukast Sodium | 118 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 35 |
| Losartan Potassium | Losartan Potassium | 100 | 45 |
| Eliquis | Apixaban | 88 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 41 |
| Metformin Hcl | Metformin Hcl | 75 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 31 |
| Ozempic | Semaglutide | 72 | 24 |
| Clonidine Hcl | Clonidine Hcl | 69 | 29 |
| Potassium Chloride | Potassium Chloride | 66 | 28 |
| Januvia | Sitagliptin Phosphate | 64 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 17 |
| Trazodone Hcl | Trazodone Hcl | 59 | 21 |
| Carvedilol | Carvedilol | 58 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 25 |
| Sertraline Hcl | Sertraline Hcl | 55 | 18 |
| Meloxicam | Meloxicam | 50 | 18 |
| Prednisone | Prednisone | 50 | 27 |
| Cefdinir | Cefdinir | 48 | 41 |
| Famotidine | Famotidine | 45 | 20 |
| Ezetimibe | Ezetimibe | 43 | 15 |
| Simvastatin | Simvastatin | 43 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 14 |
| Finasteride | Finasteride | 39 | 13 |
| Jardiance | Empagliflozin | 38 | 14 |
| Buspirone Hcl | Buspirone Hcl | 37 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 15 |
| Nystatin | Nystatin | 35 | 18 |
| Irbesartan | Irbesartan | 34 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 16 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 17 |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 12 |
| Ramipril | Ramipril | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 15 |
| Sodium Chloride | 0.9 % Sodium Chloride | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | 15 |
| Ondansetron Odt | Ondansetron | 25 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | 11 |
| Bumetanide | Bumetanide | 23 | 11 |
| Cephalexin | Cephalexin | 23 | 16 |
| Glipizide | Glipizide | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 11 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 16 |
| Levofloxacin | Levofloxacin | 18 | 14 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Sucralfate | Sucralfate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $200.77 · 11 records | ABBVIE INC. | BREZTRI, MOUNJARO, REXULTI, TRELEGY ELLIPTA, VRAYLAR, Veozah, XIFAXAN, Xhance | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error